HOSPITAL FOR SPECIAL SURGERY
1. Target Overview & Investment Thesis
HOSPITAL FOR SPECIAL SURGERY is a 200-bed under-performing / distressed in NEW YORK, NY with $1.12B in net patient revenue and a -29.3% operating margin. The hospital serves a payer mix of 38.2% Medicare, 0.3% Medicaid, and 61.6% commercial.
Thesis: Undervalued. Our ML models identify $82.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -29.3% to -21.9% (+736bps).
| Net Revenue HCRIS | $1.12B |
| Current EBITDA COMPUTED | $-328.6M |
| Operating Margin COMPUTED | -29.3% |
| Occupancy HCRIS | 37.3% |
| Revenue / Bed COMPUTED | $5.6M |
| Net-to-Gross HCRIS | 40.9% |
| Distress Probability ML | 45.6% |
2. Market Context & Competitive Position
NY has 196 Medicare-certified hospitals with a median operating margin of -17.5%. The target's margin of -29.3% places it below the state median. Among 99 size-comparable peers (100-400 beds), the median margin is -17.4%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (100-400), prioritizing same-state peers. 99 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| HOSPITAL FOR SPECIAL SURGERY (Target) | NY | 200 | $1.12B | -29.3% |
| NYC HEALTH+HOSPITAL/KINGS COUN | NY | 381 | $1.03B | -15.0% |
| ST. FRANCIS HOSPITAL | NY | 364 | $889.3M | 2.0% |
| WHITE PLAINS HOSPITAL | NY | 292 | $884.7M | 8.7% |
| ELMHURST HOSPITAL CENTER | NY | 358 | $862.7M | -9.5% |
| ROSWELL PARK CANCER INSTITUTE | NY | 142 | $772.3M | -40.1% |
| VASSAR BROTHERS MEDICAL CENTER | NY | 340 | $735.1M | -2.6% |
| UHS HOSPITALS | NY | 394 | $710.0M | -22.4% |
| SOUTH SHORE UNIVERSITY HOSPITA | NY | 312 | $700.5M | -38.5% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $82.5M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $23.5M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $22.4M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $22.2M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $13.6M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $718K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-328.6M |
| + RCM Uplift | +$82.5M |
| Pro Forma EBITDA | $-246.1M |
| Current Margin | -29.3% |
| Pro Forma Margin | -21.9% |
| WC Released (1x) | $43.0M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-505.6M | $-1.34B | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-505.6M | $-1.64B | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-455.0M | $-1.53B | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-455.0M | $-1.81B | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-556.1M | $-1.59B | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-556.1M | $-1.93B | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 99 hospitals with 100-400 beds
- Same-state prioritization (n=100)
- Comp margins: P25=-27.4% / P50=-17.4% / P75=-9.4%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.